Error loading player: No playable sources found

CASSS Welcome and CMC Strategy Forum 2025 Introductory Comments & Workshop I - Digital Transformation: AI and Data Analytics to Accelerate Development Timelines

Date
January 27, 2025
This product is not available for individual purchase, but it is available as part of the following products:

Forum Co-Chairs: Natalie Ciaccio, Vir Technology and Marc Verhagen, Sanofi

The generation of technical data to support the development and manufacture of pharmaceutical products and associated regulatory submissions is fundamental to the pharmaceutical industry. The recent boom in artificial intelligence (AI) systems and large language models (LLM) has resulted in increased interest in the capability of these systems to support industry activities. By embracing technological advancement, the biopharmaceutical industry can make significant strides in reducing submission timelines and accelerating the delivery of therapeutics. This session will include discussion on current practices with examples of how structured data, digitalization, AI, and generative AI (GenAI) are being leveraged to support pharmaceutical development, manufacturing, and standardized regulatory authoring/submission with dynamic review. The focus will be on opportunities to improve efficiency or accelerate development timelines. Discussion will include considerations for emerging technologies and forward-looking approaches for analytical data modeling.

Different aspects of the use of AI or LLMs during CMC development will be discussed including:

• Use of AI in drug discovery/developability – modeling of protein structure and properties based on sequence

• Bioprocess/ cell culture optimization using predictive analysis

• Stability modeling using AI and/or machine learning

• Leveraging commercial manufacturing data/modeling to optimize process conditions

• Automated generation of regulatory documents using LLM

Session Speakers:

The Challenge and Criticality of Data Contextualization to Support Effective AI/ML/Modeling in Bioprocess Development – an Industrial Case Study

Christian Airiau, Sanofi

Development of Realistic and Safe AI/ML Applications for Biotherapeutic Characterization and Process Development
Jeremy Shaver, Pfizer, Inc.

A “One-Click” Submission with AI and Digital Authoring

Kabir Ahluwalia, Amgen Inc.

Practical and Regulatory Considerations for Machine Learning Models Applied to Process Development and Control

Ben Stevens, GlaxoSmithKline


Related Products

Thumbnail for WATCH NOW: How to Maximize Value from Protein Metrics’ New Multi-Protein Quantitation Workflows | Presented by Protein Metrics, LLC
WATCH NOW: How to Maximize Value from Protein Metrics’ New Multi-Protein Quantitation Workflows | Presented by Protein Metrics, LLC
This Technical Seminar will be available to watch on demand 24/7 before and during the Symposium. Click on this session to access the presentation video…
Thumbnail for Welcome Day 3 & Plenary Session 7 - Navigating the Small and Virtual Business Landscape: Managing More with Less
Welcome Day 3 & Plenary Session 7 - Navigating the Small and Virtual Business Landscape: Managing More with Less
In the rapidly evolving biotechnology sector, small and virtual companies play pivotal roles in innovation and development…
Thumbnail for Workshop II - Case Studies for Applying Patient Centric Quality Standards & Workshop II Panel Discussion – Case Studies for Applying Patient Centric Quality Standards & Closing Remarks
Workshop II - Case Studies for Applying Patient Centric Quality Standards & Workshop II Panel Discussion – Case Studies for Applying Patient Centric Quality Standards & Closing Remarks
This session presents cases studies and practical experiences from industry on implementing the advanced concepts of patient-centric quality standards. This includes challenges observed and examples from protein therapeutics as well as cell & gene therapies…
Thumbnail for CASSS Welcome and CMC Strategy Forum 2025 Introductory Comments & Workshop I - Approaches to Developing an Enhanced Understanding of Product Quality Expectations
CASSS Welcome and CMC Strategy Forum 2025 Introductory Comments & Workshop I - Approaches to Developing an Enhanced Understanding of Product Quality Expectations
Forum Co-Chairs: Fiona Cornel, _Health Canada, _JR Dobbins, _Eli Lilly and Company,_ Doug Richardson,_ Merck & Company, Inc…